These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

556 related articles for article (PubMed ID: 34253638)

  • 1. Single-cell RNA sequencing reveals distinct cellular factors for response to immunotherapy targeting CD73 and PD-1 in colorectal cancer.
    Kim M; Min YK; Jang J; Park H; Lee S; Lee CH
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34253638
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting CD73 limits tumor progression and enhances anti-tumor activity of anti-PD-1 therapy in intrahepatic cholangiocarcinoma.
    Sun BY; Zhang D; Gan W; Wu JF; Wang ZT; Sun GQ; Zhou J; Fan J; Yi Y; Hu B; Zhang BH; Qiu SJ
    J Cancer Res Clin Oncol; 2024 Jul; 150(7):348. PubMed ID: 39002018
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Additive Effect of CD73 Inhibitor in Colorectal Cancer Treatment With CDK4/6 Inhibitor Through Regulation of PD-L1.
    Noh JY; Lee IP; Han NR; Kim M; Min YK; Lee SY; Yun SH; Kim SI; Park T; Chung H; Park D; Lee CH
    Cell Mol Gastroenterol Hepatol; 2022; 14(4):769-788. PubMed ID: 35843546
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single-Cell Phenotyping of CD73 Expression Reveals the Diversity of the Tumor Immune Microenvironment and Reflects the Prognosis of Bladder Cancer.
    Izawa M; Tanaka N; Murakami T; Anno T; Teranishi Y; Takamatsu K; Mikami S; Kakimi K; Imamura T; Matsumoto K; Oya M
    Lab Invest; 2023 Apr; 103(4):100040. PubMed ID: 36870289
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts.
    Capasso A; Lang J; Pitts TM; Jordan KR; Lieu CH; Davis SL; Diamond JR; Kopetz S; Barbee J; Peterson J; Freed BM; Yacob BW; Bagby SM; Messersmith WA; Slansky JE; Pelanda R; Eckhardt SG
    J Immunother Cancer; 2019 Feb; 7(1):37. PubMed ID: 30736857
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs.
    Allard B; Pommey S; Smyth MJ; Stagg J
    Clin Cancer Res; 2013 Oct; 19(20):5626-35. PubMed ID: 23983257
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Upregulation of PD-1 follows tumour development in the AOM/DSS model of inflammation-induced colorectal cancer in mice.
    Yassin M; Sadowska Z; Djurhuus D; Nielsen B; Tougaard P; Olsen J; Pedersen AE
    Immunology; 2019 Sep; 158(1):35-46. PubMed ID: 31429085
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conversion of ATP to adenosine by CD39 and CD73 in multiple myeloma can be successfully targeted together with adenosine receptor A2A blockade.
    Yang R; Elsaadi S; Misund K; Abdollahi P; Vandsemb EN; Moen SH; Kusnierczyk A; Slupphaug G; Standal T; Waage A; Slørdahl TS; Rø TB; Rustad E; Sundan A; Hay C; Cooper Z; Schuller AG; Woessner R; Borodovsky A; Menu E; Børset M; Sponaas AM
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32409420
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting CD73 with AB680 (Quemliclustat), a Novel and Potent Small-Molecule CD73 Inhibitor, Restores Immune Functionality and Facilitates Antitumor Immunity.
    Piovesan D; Tan JBL; Becker A; Banuelos J; Narasappa N; DiRenzo D; Zhang K; Chen A; Ginn E; Udyavar AR; Yin F; Paprcka SL; Purandare B; Park TW; Kimura N; Kalisiak J; Young SW; Powers JP; Schindler U; Sivick KE; Walters MJ
    Mol Cancer Ther; 2022 Jun; 21(6):948-959. PubMed ID: 35405741
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting integrin α5 in fibroblasts potentiates colorectal cancer response to PD-L1 blockade by affecting extracellular-matrix deposition.
    Lu L; Gao Y; Huang D; Liu H; Yin D; Li M; Zheng J; Wang S; Wu W; Zhao L; Bi D; Zhang Y; Song F; Xie R; Wang J; Qin H; Wei Q
    J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38040421
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
    Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H
    J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual role of CD73 as a signaling molecule and adenosine-generating enzyme in colorectal cancer progression and immune evasion.
    Lian W; Jiang D; Lin W; Jiang M; Zhang Y; Wang H; Zhao L
    Int J Biol Sci; 2024; 20(1):137-151. PubMed ID: 38164172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single-cell transcriptome analysis reveals TOX as a promoting factor for T cell exhaustion and a predictor for anti-PD-1 responses in human cancer.
    Kim K; Park S; Park SY; Kim G; Park SM; Cho JW; Kim DH; Park YM; Koh YW; Kim HR; Ha SJ; Lee I
    Genome Med; 2020 Feb; 12(1):22. PubMed ID: 32111241
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Potential Value of Immunotherapy in Colorectal Cancers: Review of the Evidence for Programmed Death-1 Inhibitor Therapy.
    Toh JWT; de Souza P; Lim SH; Singh P; Chua W; Ng W; Spring KJ
    Clin Colorectal Cancer; 2016 Dec; 15(4):285-291. PubMed ID: 27553906
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The P2X7 receptor modulates immune cells infiltration, ectonucleotidases expression and extracellular ATP levels in the tumor microenvironment.
    De Marchi E; Orioli E; Pegoraro A; Sangaletti S; Portararo P; Curti A; Colombo MP; Di Virgilio F; Adinolfi E
    Oncogene; 2019 May; 38(19):3636-3650. PubMed ID: 30655604
    [TBL] [Abstract][Full Text] [Related]  

  • 16. m
    Wang L; Hui H; Agrawal K; Kang Y; Li N; Tang R; Yuan J; Rana TM
    EMBO J; 2020 Oct; 39(20):e104514. PubMed ID: 32964498
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
    Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
    J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor Infiltration with CD20
    Hansen FJ; Wu Z; David P; Mittelstädt A; Jacobsen A; Podolska MJ; Ubieta K; Brunner M; Kouhestani D; Swierzy I; Roßdeutsch L; Klösch B; Kutschick I; Merkel S; Denz A; Weber K; Geppert C; Grützmann R; Bénard A; Weber GF
    Int J Mol Sci; 2022 May; 23(9):. PubMed ID: 35563553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer immunotherapy with PI3K and PD-1 dual-blockade via optimal modulation of T cell activation signal.
    Isoyama S; Mori S; Sugiyama D; Kojima Y; Tada Y; Shitara K; Hinohara K; Dan S; Nishikawa H
    J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34446575
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers.
    Gray MJ; Gong J; Hatch MM; Nguyen V; Hughes CC; Hutchins JT; Freimark BD
    Breast Cancer Res; 2016 May; 18(1):50. PubMed ID: 27169467
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.